Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Chemo-radiotherapy With Capecitabine for Pancreatic Cancer
NCT00658840Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2006
- Primary completion
- Jun 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in pancreatic carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Tumor Response Rate, Local Control Rate and 1 more. Status: unknown.
02
Drugs
capecitabine
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT00658840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658840.